AT2433, an indolocarbazole antitumor antibiotic, is structurally distinguished by its aminodideoxypentose-containing disaccharide and asymmetrically halogenated N-methylated aglycon. Cloning and sequence analysis of AT2433 gene cluster and comparison of this locus with that encoding for rebeccamycin and the gene cluster encoding calicheamicin present an opportunity to study the aminodideoxypentose biosynthesis via comparative genomics. The locus was confirmed via in vitro biochemical characterization of two methyltransferases-one common to AT2433 and rebeccamycin, the other unique to AT2433-as well as via heterologous expression and in vivo bioconversion experiments using the AT2433 N-glycosyltransferase. Preliminary studies of substrate tolerance for these three enzymes reveal the potential to expand upon the enzymatic diversification of indolocarbazoles. Moreover, this work sets the stage for future studies regarding the origins of the indolocarbazole maleimide nitrogen and indolocarbazole asymmetry.
Introduction
Deoxysugars are an essential class of naturally occurring carbohydrates. These deoxygenated and often highly functionalized sugars present distinctive hydrophobic and hydrophilic characteristics critical to their role in dictating specificity on a tissue, cellular, and/or molecular level. Among the deoxysugars, deoxyhexoses are arguably the most diverse and best studied to date [1, 2] . In contrast, while functionalized deoxypentoses append a variety of diverse bioactive bacterial secondary metabolites ( Figure 1A) , the biosynthesis of these important sugar attachments remains largely undefined. Classical metabolic labeling of esperamicin ( Figure 1A, 3) suggested that the esperamicin aminodideoxypentose (2,4-dideoxy-4-methylamino-a-L-xylopyranoside) derived from glucose [3] , presumably by loss of C-6 as CO 2 in a fashion reminiscent of the UDP-D-xylose pathway common to primary metabolism [4, 5] . The elucidation of the calicheamicin (Figure 1A, 1) gene locus [6] , followed by the overexpression and biochemical characterization of CalS8 as a UDP-a-Dglucose dehydrogenase, provided further support for C-6 oxidative decarboxylation as a general point of divergence to commit nucleotide sugars to aminodideoxypentose biosynthesis [7] . While the early studies on the biosynthesis of avilamycin ( Figure 1A, 4) implicated ribose as the progenitor of the deoxypentose [8] , recent work by Bechthold and coworkers revealed AviE2 to function as a UDP-a-D-glucuronic acid decarboxylase-also consistent with glucose as the deoxypentose progenitor in orthosomycin biosynthesis [9] .
Among the naturally occurring indolocarbazole alkaloids, AT2433 ( Figure 1B, 6) shares the unique aminodideoxypentose common to the enediynes calicheamicin ( Figure 1A , 1) and esperamicin ( Figure 1A , 3) [10, 11] . The indolocarbazoles-bacterial secondary metabolites with potent antitumor and neuroprotective propertiesall share a common indolo [2,3-a] pyrrolo [3,4-c] carbazole core but they are often subdivided into two structural subgroups [12] . The first includes AT2433 (Figure 1B, 6 ) and rebeccamycin ( Figure 1B, 7) and is structurally defined by a common b-N-glucoside appendage. Rebeccamycin is a potent stabilizer of the topoisomerase I-DNA covalent complex. However, the addition of the cationic aminodideoxypentose in 6 abolishes topoisomerase I inhibition while enhancing DNA affinity [13] [14] [15] . The second indolocarbazole structural group, exemplified by staurosporine ( Figure 1B, 8) , contains a signature bridging of indole nitrogens by a single glycosyl moiety at C-1 0 and C-5 0 , and members of this structural subgroup are potent inhibitors of protein kinases A, C, and K [16, 17] . The clinical development of several indolocarbazole derivatives from both classes has been pursued, including the potent topoisomerase I poison NB-506, the promising kinase inhibitors UCN-01, CEP-701/751, and K252a, and a water-soluble analog (NSC 655649) which, by virtue of semisynthetic modification, is a potent topoisomerase II inhibitor [18] [19] [20] [21] [22] .
Much is known regarding the biosynthesis of indolocarbazoles. For example, the gene clusters encoding for the production of 7 (from Saccharothrix aerocolonigenes ATCC39243) [23] [24] [25] and 8 (from Streptomyces sp. TP-A0274) [26] have been elucidated and many of the gene functions subsequently established via gene inactivation or heterologous expression. A recent elegant heterologous combinatorial in vivo reconstitution of components of the 7 pathway also led to the identification of 12 bisindole intermediates [27] and a five-stage biosynthetic pathway for indolocarbazole natural products based upon the 7 pathway has been proposed [23] [24] [25] [26] . With respect to enzymes required for 7 biosynthesis, RebG [28] , RebH [29] , RebO [30, 31] , RebD [31] , and RebM [28, 32] have been confirmed biochemically as the N-glucosyltransferase, tryptophan halogenase, 7-chloro-tryptophan oxidase, chromopyrrolic acid synthase, and sugar-4-O-methyltransferase, respectively. Recent efforts toward the enzymatic diversification of indolocarbazoles revealed RebG to N-glucosylate unnatural aglycons and also provided indolocarbazole *Correspondence: jsthorson@pharmacy.wisc.edu N-glucoside regioisomers [28] , while RebM could alklyate unnatural substrates and efficiently utilize nonnatural cofactor analogs [28, 32] . The late steps of 8 biosynthesis have also been recently elucidated via in vivo strategies to be N-12 glycosylation (StaG) followed by a unique P450 (StaN)-catalyzed formation of the second C-5 0 -carbohydrate-N-13-indole connection, and StaG was also utilized for indolocarbazole diversification [33] .
Despite the remarkable body of work described above, the study of 6 biosynthesis remains an attractive target, as this pathway promises a variety of new biosynthetic targets and tools. In comparison to other indolocarbazole alkaloids, 6 is the only naturally occurring indolocarbazole to have an N-methylated and asymmetrically halogenated indolocarbazole core. In addition, 6 contains a novel cationic pentose-a structural motif, as described above, also shared by enediynes 1 and 3, which serves as a key DNA recognition element for these structurally diverse natural products. This unique structural, and presumably genotypic, element shared by 1, 3, and 6 suggests that a comparison between the 1, 6, and 7 gene clusters should quickly identify genes common for aminopentose biosynthesis and thereby present a basis from which to more accurately predict the biosynthesis of uniquely functionalized pentoses. Here we report the elucidation of the 6 biosynthetic gene cluster from Actinomadura melliaura. The locus was confirmed via in vitro biochemical characterization of two methyltransferases (one common to 6 and 7, the other unique to 6) as well as via heterologous expression and in vivo bioconversion experiments using the 6 N-glycosyltransferase. Preliminary studies of substrate tolerance for these three enzymes reveal the potential opportunity to utilize these enzymes to expand upon the general enzymatic diversification of indolocarbazoles. The structures of (A) pentose-containing natural products calicheamicin (1), maduropeptin (2), esperamicin (3), avilamycin (4), evernimicin (5) , and (B) indolocarbazoles AT2433 (6, X = H or Cl), rebeccamycin (7) , and staurosporine (8) . The aminodideoxypentose common to 1, 3, and 6 has been highlighted by boxes.
In addition, a comparison of the 1, 6, and 7 gene loci provides, for the first time, a clear biosynthetic model for the aminodideoxypentose common to these structurally diverse natural products.
Results and Discussion
Cloning and Sequencing of the AT2433 Gene Cluster Given the notable structural and putative biosynthetic similarities between 6 and 7, degenerate primers designed to amplify two genes essential to biosynthesis of the indolocarbazole core-rebD, which encodes the chromopyrrolic acid synthase, and rebP, which encodes for a putative P450 oxidase-were used to amplify the corresponding homologs (designated atmD and atmP, respectively) from A. melliaura genomic DNA. The PCRamplified fragments were confirmed by sequencing and the confirmed A. melliaura rebD and rebP gene homologs were subsequently employed as DNA probes to screen an A. melliaura genomic library.
The A. melliaura genomic cosmid library was constructed in SuperCos2 and approximately 4000 clones from this library were screened by colony hybridization using digoxigenin (DIG)-labeled atmD and atmP. The positive clones were confirmed by PCR amplification with the same degenerate primers originally used to amplify atmD and atmP from the genomic template. Shotgun sequencing of one positive from this screen, cosmid pJST1004, revealed a 43 kb insert containing five genes highly homologous to genes involved in 7 and 8 biosynthesis and genes encoding for NDP-sugar biosynthesis. Chromosomal walking using DNA probes designed from each end of the cosmid pJST1004 insert, followed by shotgun sequencing of a total of 85 kb of contiguous A. melliauri genomic DNA, allowed for the completion of the putative biosynthetic locus for 6.
The genomic sequence of this entire 85 kb fragment (with an average GC content of 70%) was analyzed by the FRAME program [34] to reveal 48 putative open reading frames (ORFs), the preliminary annotation of which derived from BLAST analysis [35] . The sequence postulated to be relevant to 6 biosynthesis is highlighted in Figure 2 and resides in a 45 kb fragment containing 35 ORFs designated orf1-orf14. Consistent with the structure of 6, the putative ORFs identified consist of six genes (atmA, C, D, H, O, and P) involved in the indolocarbazole core biosynthesis, nine genes (atmG, G1, S7-S10, and S12-S14) involved in the construction and attachment of carbohydrates, three methyltransferase genes (atmM, M1, and S10), and four genes (atmB, E, I, and R) related to resistance or regulation. The proposed function for each of the 35 ORFs and their closest homologs are listed in Table 1 . The sequence upstream (w6 kb) to orf1 encodes for primarily hypothetical proteins (average GC content of 64.2 6 1.5%; 86.2 6 2.6% GC in the wobble position). In contrast, orf1-7 displayed an average GC content of 73.3 6 1.6% (90.6 6 2.1% GC in the wobble position) and the atm locus displayed an average GC content of 71.0 6 2.5% (93.3 6 3.2% GC in the wobble position). Similar to the orf1 5 0 region, the sequence downstream of the atm locus (orf8-14) also primarily encodes for hypothetical proteins (average GC content of 67.6 6 2.1%; 84.7 6 3.6% GC in the wobble position). On the basis of Table 1. functional and GC content, we postulate the minimal 6 biosynthetic gene cluster to be contained between atmA and atmI.
Characterization of N-Glucosyltransferase AtmG Of the two putative glycosyltransferase genes (atmG and atmG1) within 6 gene cluster, atmG was proposed to encode the requisite N-glycosyltransferase based upon homology to the known indolocarbazole N-glycosyltransferase genes rebG and staG. Overproduction of AtmG in Escherichia coli under a variety of conditions led to insoluble protein, consistent with previous work on RebG [28] . Following the strategy previously employed [28, 33, 36] , the same AtmG-E. coli overexpression strain was subsequently analyzed via bioconversion for its ability to N-glycosylate indolocarbazoles. Bioconversion of aglycon surrogates 9 and 12 followed by HPLC analysis ( Figure 3A ) revealed new products with characteristic indolocarbazole absorption profiles. LC-MS characterization was consistent with the formation of products 10/11 with an estimated bioconversion yield of 99% and trace production of 13/14, respectively. Similar biochemical studies with RebG revealed the same ability to generate a mixture of regioisomers (10/11 and 13/14) [28] . Under the same conditions, only starting material was recovered from control E. coli strains containing an expression vector lacking the N-glucosyltransferase gene. Notably, the outcome of this cumulative set of experiments is clearly consistent with the gene atmG as encoding the requisite N-glucosyltransferase involved in 6 biosynthesis.
Characterization of O-and N-Methyltransferases AtmM and AtmM1
Based upon homology to RebM, AtmM was proposed to function as the required Glc-4 0 -O-methyltransferase in the AT2433 pathway. The recent biochemical characterization of RebM revealed the rebeccamycin Glc-4 0 -Omethylase to utilize both ''unnatural'' substrates and S-adenosyl-methionine surrogates [28, 32] . Paralleling the earlier RebM study, the atmM gene was overexpressed in E. coli and the corresponding AtmM purified to homogeneity. Figure 3B reveals the purified AtmM could efficiently methylate a variety of indolocarbazoles in vitro. Specifically, compounds 10, 13, and 15-19 were converted to compounds 20, 21, and 22-26, with yields ranging from 8% to 99%. As controls, product was not detected in assays lacking AtmM or SAM or in assays with 4 0 -O-methylated substrates (e.g., Figure 3C, 7) . All products were characterized by LC-MS and compounds 20-22 and 24 were shown to coelute with previously characterized standards [28] . Interestingly, AtmM displayed a slightly broader substrate scope in comparison to RebM and allowed for the production of new compounds 25 and 26. Most important, the outcome of this cumulative set of experiments is also clearly consistent with the gene atmM as encoding the requisite Glc-4 0 -Omethylase involved in 6 biosynthesis. The sequence analysis of atmM1 revealed a thiopurine S-methyltransferase domain implicating AtmM1 as the putative candidate for the 6 maleimide N-methyltransferase. To assess this postulation, atmM1 was overexpressed in E. coli and the catalyst tested both in vivo and in vitro. The atmM1-E. coli strain was found to convert 17b to 27b via bioconversion (data not shown), while in vitro assays revealed AtmM1 could methylate a variety of indolocarbazoles ( Figure 3C ). Specifically, compounds 17b, 24b, 30, and 7 were converted to compounds 27b, 28b, 31, and 32 (the complete characterization of which has been previously reported [37] [38] [39] [40] ), respectively, with yields ranging from 12% to 96% as determined via LC-MS. As controls, products were not detected in assays lacking AtmM1 or SAM. While N-methylmaleimido analogs (16a, 16b, and 19) and derivatives lacking an aglycon carbonyl (9, 10/11) could be processed by AtmG and/or AtmM, neither set could be methylated by AtmM1, further supporting the regiospecificity of AtmM1 and the importance of the C-7 carbonyl for recognition by AtmM1. Notably, the outcome of this cumulative set of experiments is clearly consistent with the gene atmM1 as encoding the requisite maleimide N-methylase involved in 6 biosynthesis. Unlike the confirmed steps catalyzed by AtmG and AtmM described above, which are common to both 6 and 7 biosynthesis, the AtmM1-catalyzed N-methylation is unique to the 6 pathway and thus strongly supports our assignment of this locus as encoding for 6 biosynthesis.
A variety of assays were subsequently performed in an attempt to delineate the timing of N-glucosylation and N-versus O-methylation in 6 biosynthesis. Under identical conditions, the N-methylation of 7, 17b, or 30 led to the production of 32, 27b, or 31 in 38%, 96%, and 12.4% yield, respectively ( Figure 3C ). While not a direct kinetic assessment, this preliminary study implicates N-glycosylated indolocarbazoles to be slightly better substrates for AtmM and thus suggests N-methylation, like O-methylation [41] , may occur after N-glucosylation. A similar preliminary study designed to probe N-versus O-methylation (AtmM1 versus AtmM) revealed the AtmM1-catalyzed conversion of 24b to 28b to proceed with 86% yield (Figure 3C, iii) , while AtmM-catalyzed conversion of 27b to 28b proceeded in 67% yield ( Figure 3C , iv). This study, again while not a kinetic analysis, suggests the order of N-or O-methylation to be of fairly indiscriminate nature.
In the context of natural products, simple modifications, such as methylation, can wield remarkable effects upon their pharmacological properties [42] [43] [44] . For example, alterations of indolocarbazole sugar-4 0 -O-methylation and/or the aglycon maleimide N-methylation modulate cytotoxicity and/or the specific molecular interactions between the indolocarbazole and DNA and/ or protein targets [28, [43] [44] [45] . Moreover, alterations of these specific molecular interactions between the small molecule and the target are not always predictive of the ultimate cytotoxic potency. The recent biochemical characterization of RebM revealed the rebeccamycin Glc-4 0 -O-methylase to utilize both ''unnatural'' substrates and S-adenosyl-methionine cofactor analogs [28, 32] . Given the slightly broader substrate scope demonstrated by AtmM (in comparison to RebM), and the demonstrated ability of AtmM1 to also N-methylate indolocarbazole surrogates, these new indolocarbazole-modifying enzymes may prove to be beneficial new tools for extending the structural diversity of this clinically relevant class of natural product.
Aminopentose Biosynthesis and Attachment
Sequence analysis of the newly confirmed 6 gene cluster revealed seven NDP-sugar biosynthetic genes (atmS7-10, atmS12-14). Interestingly, homologs for each of these 6 NDP-sugar genes (calS7-10, calS12-14) were also found in the 1 biosynthetic locus with % identity/ % similarity ranging from 51/65 to 66/76. In comparison, the seven genes in 6 gene cluster are more closely colocalized than their counterparts in the 1 locus. Based on the putative functions of this conserved set of gene products, a model for aminodideoxypentose biosynthesis is proposed ( Figure 4A ). In this set, the deduced product of atmS7 is similar to a family of glucose-1-phosphate nucleotidylyltransferases which initiate most sugar biosynthetic pathways by presenting the sugar nucleotide. The deduced product of atmS8 resembles CalS8, a biochemically characterized UDP-a-D-glucose dehydrogenase (UDPGlcDH) previously postulated to be involved in the 1 aminodideoxypentose biosynthetic pathway [7] . Both AtmS9 and CalS9 show considerable similarity to UDP-glucose 4-epimerases of Bacillus cereus ATCC 14579 (38% identity, 59% similarity; Table 1 ) and UDPglucuronate decarboxylases of Mus musculus (33% identity, 50% similarity; Table 1 ). Several UDP-glucuronate decarboxylases have been characterized in the biosynthetic pathway of UDP-xylose required for primary metabolism in plants [4, 46] , vertebrates [47] [48] [49] , fungi [50] , and bacteria [51] , and Hofmann et al. recently confirmed AviE2 as the UDP-glucuronate decarboxylase en route to L-lyxose [9] .
The final aminodideoxypentose product requires C-2 deoxygenation, a step known to require two enzymes (NDP-4-ketosugar 2,3-dehydratase and subsequent 2,3-reductase) within the biosynthesis of 2,6-dideoxyhexoses [52, 53] . Genes encoding for homologs for a putative 2,3-dehydratase (AtmS14/CalS14) and potential 2,3-reductase (AtmS12/CalS12) are conserved within both the 1 and 6 loci, and thus this comparison presents the first compelling evidence from which to propose a similar strategy for aminodideoxypentose C-2-deoxygenation. The deduced products of atmS13/calS13 resemble NDP-sugar aminotransferases [54] [55] [56] [57] [58] [59] and are postulated to catalyze the subsequent amine installation at the C-4 position. Previous studies, in collaboration with Liu and coworkers, identified CalS13 as the TDP-6-deoxy-a-D-glycero-L-threo-4-hexulose-4-aminotransferase in the 1 pathway [60] . In contrast, the current comparative genomics approach clearly reveals CalS13 to be the AtmS13 homolog (62% identity, 76% similarity) and thereby implicates a potential dual activity for this aminotransferase. While this needs to be confirmed biochemically, to our knowledge this would be the first example of an NDP-ketosugar aminotransferase capable of operating upon both NDP-hexose and NDP-pentose scaffolds. The final tailoring event is postulated to be catalyzed by the methyltransferase homologs AtmS10/ CalS10. Interestingly, the original labeling studies of 4 revealed all alkyl carbons within the 4 N-alkyl-aminodideoxypentose (esperamicin A 1c , A 1b , and A 1 corresponding to N-methyl-, N-ethyl-, and N-isopropyl-, respectively) to derive from methionine [3] . Given what is known about S-adenosylmethionine-dependent methyltransferase catalysis, future characterization of AtmS10/CalS10 may expose a novel enzymatic mechanism for this potential sequential alkylation event. Finally, the gene atmG1 encodes for a 415 amino acid O-glycosyltransferase homolog [61, 62] postulated to catalyze the final attachment of the aminopentose, the timing of which remains to be deciphered.
Additional Unique Features-Halogenation and the Source of Indolocarbazole Amine
The first step in indolocarbazole biosynthesis is flavindependent halogenation catalyzed by RebH in 7 biosynthesis [23, 24, 27, 29] . The AT2433 locus encodes for a RebH homolog (AtmH), but unlike the 7 loci lacks a gene encoding for the requisite flavin reductase (rebF). The next step (the flavin-dependent L-amino acid oxidase RebO/AtmO) catalyzes the oxidative deamination of 7-chloro-L-tryptophan to 7-chloroindole-3-pyruvic acid ( Figure 4B, 36, 37 ) [30] . The core fusion proceeds via RebD/AtmD-catalyzed oxidative dimerization of Trp-derived monomers (e.g., [38] [39] [40] to form chromopyrrolic acid ( Figure 4B , 41-43) [31] , and recent studies revealed RebO/RebD were able to tolerate nonhalogenated, monohalogenated, or dihalogenated substrates [27, 30, 31] . Although many of the early steps within indolocarbazole core formation are fairly well understood, the source of the maleimide nitrogen within 38-40 remains controversial.
Early staurosporine labeling experiments revealed the core nitrogen to be nontryptophan in origin [63] . Recent in vitro studies revealed the maleimide nitrogen within 41-43 derived from indole 3-pyruvate imine (38-40) [31] . However, the in vivo nitrogen source en route to imines 38-40 is unknown. Interestingly, the AT2433 gene cluster contains a gene (atmA) directly upstream of atmS10, the product of which displays high homology to OxyD (56% identity, 65% similarity)-a glutaminedependent amidotransferase involved in tetracycline biosynthesis in Streptomyces rimosus (Table 1) . We postulate AtmA may catalyze nitrogen installation (to provide imine 38 or 40). Furthermore, given the indiscriminate nature of RebD (and presumably AtmD), we propose that the unique substrate specificities of AtmA and AtmO may dictate the final formation of asymmetrically halogenated aglycon in AT2433. This unique feature may also present additional opportunities for the combinatorial biosynthesis of differentially halogenated indolocarbazole aglycons.
Resistance and Regulation
Based on database comparison, two gene products may be related to AT2433 biosynthesis regulation. The first, AtmR, is homologous to RebR and StaR (43% identity, 56% similarity)-annotated as putative transcriptional activators of 7 and 8 biosynthetic pathways, respectively [23, 26] . As putative transporters associated with AT2433 biosynthesis, atmB encodes a 435 amino acid protein homologous to a putative antiporter from Amycolatopsis balhimycina (64% identity, 80% similarity; Table 1 ), while atmI encodes a product which resembles a putative transmembrane efflux protein from Streptomyces coelicolor A3(2) (44% identity, 63% similarity; Table 1 ). Finally, atmE reveals low homology (33% identity, 54% similarity) with a putative regulatory protein from Frankia sp. EAN1pec (Table 1) .
Significance
The natural product AT2433, an indolocarbazole antitumor antibiotic, is structurally distinguished by its unique aminodideoxypentose-containing disaccharide and asymmetrically halogenated N-methylated aglycon. This work reveals the first glimpse of the AT2433 gene locus with locus confirmation via in vivo bioconversion and in vitro biochemical assay using AtmG, AtmM, and AtmM1. Preliminary studies of substrate tolerance suggest the potential opportunity to utilize these three enzymes for future indolocarbazole enzymatic diversification. Comparative genomics based upon the rebeccamycin, calicheamicin, and newly cloned AT2433 gene loci also provides, for the first time, a biosynthetic model for the aminodideoxypentose common to these structurally diverse natural products. Moreover, this work sets the stage for further studies regarding the origin of indolocarbazole maleimide nitrogen and factors which dictate the biosynthesis of asymmetric indolocarbazoles. Cumulatively, this work has both biosynthetic significance and the potential for clinical impact.
Experimental Procedures
Bacterial Strains, Culture Conditions, Vectors, and Reagents Actinomadura melliaura sp. nov. SCC 1655 was grown on ISP2 agar medium (Bacto Laboratories Pty Ltd, Liverpool, NSW, Australia) and in liquid medium TSB medium (Bacto) at 30ºC. Escherichia coli DH5a or NovaBlue (Novagen, EMD Biosciences, San Diego, CA) competent cells were used for standard subcloning, E. coli XL-1 Blue MRF 0 (Stratagene, La Jolla, CA) for cosmid library construction, and E. coli BL21(DE3) (Novagen) for gene expression and in vivo bioconversion strains. All E. coli strains were grown and transformed as described previously [64] . SuperCos2, a SuperCos1 (Stratagene) derivative vector lacking the neomycin resistance gene, was used for cosmid library construction. Vectors pEZSeq and pSMART-LCkan (Lucigen, Middleton, WI) were utilized for shotgun library construction for cosmid sequencing, while pGEM-Teasy (Promega, Madison, WI) was used for PCR cloning and sequencing. Vectors pET-30Xa/LIC and pET28a (Novagen) were used for gene expression. Biochemicals, chemicals, media, restriction enzymes, and other molecular biology reagents were from standard commercial sources. All indolocarbazole derivatives employed for enzyme assays and bioconversion experiments have been described elsewhere [11, 28, 45, 65] .
DNA Isolation, Manipulation, and Cloning
Plasmid and cosmid DNA were isolated from E. coli strains using Qiagen miniprep and large construct kits (Qiagen, Valencia, CA). The isolation of DNA fragments from excised agarose was accomplished with the Qiagen gel clean kit (Qiagen). Restriction endonuclease digestion, ligation, and transformation were performed according to standard procedures [64] or manufacturers' recommendations. Chromosomal DNA isolation from A. melliaura SCC 1655 was accomplished via previously described methods [66] and PCR amplifications were carried out on a GeneAmp PCR system 9700 (Perkin-Elmer/ABI, Foster City, CA) using either PfuTurbo DNA polymerase (Stratagene) or TaKaRa LA-Taq DNA polymerase (Takara Mirus Bio, Madison, WI). For Southern analysis, DIG labeling of DNA probes, hybridization, and detection were performed according to the protocols provided by the manufacturer (Roche Applied Science, Indianapolis, IN). For PCR amplification from genomic DNA and cloning of atmD gene, the following pair of degenerate primers was used: 5 0 -TCGCCCRCGAGGAGATGATCC-3 0 (forward) and 5 0 -GTCGATCSCGAACAGCGCRCTG-3 0 (reverse); for the atmP gene: 5 0 -TGGCTGGTYTTCMTSGACCCGCC-3 0 (forward) and 5 0 -TTCGTGGTSGTCTCGTGSCCGGC-3 0 (reverse). PCR conditions were as follows: 5 min at 95ºC, 30 cycles (30 s at 95ºC, 30 s at 57ºC, 1 min at 72ºC), and 10 min at 72ºC with 1 U LA-Taq DNA polymerase. All primers were synthesized by Integrated DNA Technologies (Coralville, IA).
Genomic Library Construction and Screening
A. melliaura SCC 1655 genomic DNA was partially digested with Sau3AI to give fragments averaging 30-40 kb in size. These fragments were dephosphorylated with calf intestine alkaline phosphatase (CIAP) and ligated into the HpaI-and BamHI-digested cosmid vector SuperCos2. The ligation products were packaged with Gigapack III XL packaging extract (Stratagene) as described by the manufacturer and the resulting recombinant phage was used to infect E. coli XL1-Blue MRF 0 cells. The resulting genomic library was screened by colony hybridization using the PCR-amplified genes atmD and atmP as probes, respectively, and the resultant positive clones were further confirmed by PCR amplification directly from positive cosmids.
DNA Sequencing and Analysis
Shotgun libraries of each positive cosmid were generated by Lucigen and shotgun sequencing was accomplished by the UW-Madison Genome Center (University of Wisconsin, Madison). Automated sequencing was done on double-stranded DNA templates from at least 700 shotgun subclones for each cosmid. All sequencing data were subsequently assembled and edited using SeqMan software (DNAStar). ORF searches were done by using the frameplot software available at http://www.nih.go.jp/wjun/cgi-bin/frameplot-3.0b.pl. Database comparison was performed with the BLAST search tools on the server of the National Center for Biotechnology Information (Bethesda, MD). The DNA sequence has been deposited in GenBank under the accession number DQ297453.
Overexpression and Characterization of the N-Glucosyltransferase AtmG
To generate an AtmG expression construct, the atmG gene was amplified from chromosomal DNA using primers atG-EF21 (5 0 -GTCAC CATATGGCACGGGTGCTCATG-3 0 , NdeI site underlined) and atG-ER21 (5 0 -TCAGGATCCTCAACTGATCGCTGTCCTG-3 0 , BamHI site underlined). PCR conditions were as follows: 3 min at 94ºC, 30 cycles (30 s at 94ºC, 30 s at 55ºC, 1 min at 72ºC), and 10 min at 72ºC with 1 U Pfu DNA polymerase, 5% DMSO. The gel-purified amplicon was cloned into the NdeI and BamHI sites of pET28a(+) (Novagen, EMD Biosciences) and the construct was confirmed by sequencing to yield plasmid pUWG-atGT221 (designed to express an N-terminal His tag fusion protein). The bioconversion assays were accomplished in triplicate using pUW-atG221-E. coli BL21(DE3) with pET28a(+)-E. coli BL21(DE3) as the control. For each assay, a single fresh colony of E. coli BL21(DE3) was inoculated into 3 ml Luria Bertani (LB) medium containing 50 mg ml 21 kanamycin. After incubation with shaking (250 rpm) at 37ºC for 8-10 hr, an aliquot of preculture was transferred to 5 ml LB (1:100 dilution), and the culture was grown at 28ºC with shaking until A 600 = 0.6. Isopropyl-b-D-thiogalactopyranoside was subsequently added (final concentration of 0.4 mM) and the culture was grown for 1.5 hr. Compound 9 (or 12) (50 mM final concentration) was added and the culture was grown for an additional 4 hr and subsequently extracted with an equal volume of ethyl acetate. After centrifugation, the organic phase was evaporated, resuspended in 100 ml methanol, and analyzed by HPLC and LC-MS as described under Product Isolation and Characterization.
Overexpression and Characterization of the Glc-4 0 -O-Methyltransferase AtmM To generate an AtmM expression construct, the atmM gene was amplified from chromosomal DNA using primers at24M-EF31 (5 0 -GGTATTGAGGGTCGCATGACGGATATCAGCCAG-3 0 , ligation site underlined) and at24M-ER31 (5 0 -AGAGGAGAGTTAGAGCCCT AGCTGCGGCGGGCGGC-3 0 , ligation site underlined). PCR conditions were as follows: 3 min at 94ºC, 30 cycles (30 s at 94ºC, 30 s at 55ºC, 1 min at 72ºC), and 10 min at 72ºC with 1 U Pfu DNA polymerase, 5% DMSO. The gel-purified amplicon was treated and annealed with the ligation-independent cloning (LIC) sites of pET30Xa/LIC vector (Novagen) and confirmed by sequencing to yield plasmid pUWG-at24M31 (designed to express an N-terminal His tag fusion protein).
The plasmid pUWG-at24M31 containing the gene of N-His-tagged atmM was transformed in E. coli BL21(DE3) cells and a fresh colony was used to inoculate a 3 ml culture in LB medium supplemented with 50 mg ml 21 kanamycin which was grown at 37ºC with 250 rpm shaking for 8-10 hr. A 0.5 ml aliquot of this preculture was transferred to 50 ml LB supplemented with 50 mg ml 21 kanamycin in 250 ml flasks and the culture was grown at 37ºC with 250 rpm shaking for 8 hr. Approximately 10 ml of this secondary culture was transferred to 1 l LB medium grown under identical conditions until A 600 = 0.8. AtmM overexpression was induced with addition of isopropyl-b-D-thiogalactopyranoside (IPTG; final 0.4 mM concentration) and the culture was grown for an additional 17 hr at 18ºC before being harvested. Cells were harvested by centrifugation, and the cell pellet was washed twice (20 mM phosphate buffer [pH 7.5]) and then stored at 280ºC. All subsequent purification steps were accomplished at 4ºC.
The thawed cell pellet from 1 l of culture was resuspended in 30 ml of binding buffer (20 mM NaH 2 PO 4 , 500 mM NaCl, 10 mM imidazole [pH 7.5]) containing 1 mg ml 21 lysozyme and the mixture was incubated on ice for 30 min. The cells were lysed completely by French press (three rounds at 700 psi; Thermo IEC, Waltham, MA) and the cell debris was subsequently removed by centrifugation (16,000 3 g, 30 min). The supernatant fraction was filtered (0.45 mm syringe filter; Nalgene, Rochester, NY) and subjected to FPLC purification using a HisTrap HP column (1 ml; GE Healthcare Life Sciences [formerly Amersham Biosciences], Piscataway, NJ). The protein was loaded on the column with binding buffer and eluted with the same buffer using a linear imidazole gradient (10-500 mM, flow rate 1 ml min 21 , UV detection 280 nm). The desired protein fractions eluted with 100 mM imidazole were pooled, transferred into assay buffer (25 mM Tris-HCl, 20 mM NaCl, 0.5 mM DTT, 10% glycerol [pH 8.0]) via a PD-10 column (GE Healthcare Life Sciences), and concentrated (VIVASPIN 15R 10,000 MWCO; Sartorius AG [formerly Vivascience], Goettingen, Germany). The protein concentration was measured by the Bradford assay with bovine serum albumin as a standard (Bio-Rad, Hercules, CA). The protein was stored at 280ºC.
Typical assays with compounds 10, 13, and 15-19 as substrates were conducted in a total volume of 100 ml of reaction mixture (50 mM Tris-HCl [pH 8.0]), including substrate (50 mM), S-adenosylmethionine (SAM; 100 mM), and purified protein (15 mM). Reactions were initiated by the addition of AtmM and incubated at 30ºC for 3-8 hr. The assay mixture was subsequently extracted with an equal volume of ethyl acetate, the organics evaporated, and the recovered material redissolved in 100 ml of methanol and analyzed by HPLC and LC-MS as described in Product Isolation and Characterization.
Overexpression and Characterization of N-Methyltransferase AtmM1
To generate an AtmM1 expression construct, the atmM1 gene was amplified from chromosomal DNA using primers atM1U2-EF31 (5 0 -GGTATTGAGGGTCGCATGCGCCCACTTCTTTAT-3 0 , ligation site underlined) and atM1U2-ER31 (5 0 -AGAGGAGAGTTAGAGCCTCACG GGTGCCGATCCCG-3 0 , ligation site underlined). PCR conditions were as follows: 3 min at 94ºC, 30 cycles (30 s at 94ºC, 30 s at 55ºC, 1 min at 72ºC), and 10 min at 72ºC with 1 U Pfu DNA polymerase, 5% DMSO. The gel-purified amplicon was treated and annealed with the LIC sites of pET30Xa/LIC vector (Novagen) to yield plasmid pUWG-atM2U131 (designed to express an N-terminal His tag fusion protein) which was confirmed by sequencing.
The plasmid pUWG-atM2U131 was transformed in E. coli BL21(DE3) cells and a fresh colony was used to inoculate 3 ml of LB medium supplemented with 50 mg ml 21 kanamycin at 37ºC with 250 rpm shaking for 8-10 hr. A 0.5 ml aliquot of this seed culture was transferred to 50 ml LB supplemented with 50 mg ml 21 kanamycin in 250 ml flasks and the secondary culture was grown at 37ºC with 250 rpm shaking for 8 hr. Approximately 10 ml of secondary culture was transferred to 1 l LB and the culture was grown under the same conditions to A 600 = 0.8. AtmM1 overexpression was induced with addition of IPTG (final concentration 0.4 mM) and the culture was grown for an additional 17 hr at 18ºC. Cells were harvested by centrifugation, and the cell pellet was washed twice (20 mM phosphate buffer [pH 7.5]) and then stored at 280ºC.
The thawed cell pellet from 1 l of culture was resuspended in 30 ml of binding buffer (20 mM NaH 2 PO 4 , 500 mM NaCl, 10 mM imidazole [pH 7.5]) containing 1 mg ml 21 lysozyme and the mixture was incubated on ice for 30 min. The cells were lysed completely by French press (three rounds at 700 psi; Thermo IEC) and the cell debris was subsequently removed by centrifugation (16,000 3 g, 30 min). Upon purification AtmM1 lost activity, and thus assays were routinely conducted at this stage (AtmM1 was estimated to comprise approximately 30% of the soluble protein in the crude extract by SDS-PAGE). For AtmM1 purification, the supernatant fraction was filtered (0.45 mm syringe filter; Nalgene) and subjected to FPLC purification using a HisTrap HP column (1 ml; GE Healthcare Life Sciences). The protein was loaded on the column with binding buffer and eluted with the same buffer using a linear imidazole gradient (10-500 mM, flow rate 1 ml min 21 , UV detection 280 nm). The desired protein fractions eluted with 200-300 mM imidazole were pooled, transferred into assay buffer (25 mM Tris-HCl, 20 mM NaCl, 0.5 mM DTT, 10% glycerol [pH 8.0]) via a PD-10 column (GE Healthcare Life Sciences), and concentrated (VIVASPIN 15R 10,000 MWCO; Sartorius AG). The protein concentration was measured by using the Bradford assay with bovine serum albumin as a standard (Bio-Rad). The protein was stored at 280ºC.
The in vivo bioconversion experiments with AtmM1 were identical to those described for AtmG except that the overexpression strain was driven by plasmid pUWG-atM2U131 and different aglyons (10, 17b) were employed as substrates. Typical assays with compounds 7, 17b, 24b, and 30 as substrates were conducted in a total volume of 100 ml reaction mixture (50 mM Tris-HCl [pH 8.0]), including substrate (50 mM), SAM (100 mM), and AtmM1 (w15 mM). Reactions were initiated by the addition of AtmM1 and incubated at 30ºC for 3-8 hr. The assay mixture was subsequently extracted with an equal volume of ethyl acetate, the organics evaporated, and the recovered material redissolved in 100 ml methanol and analyzed by HPLC and LC-MS as described in Product Isolation and Characterization.
Product Isolation and Characterization
Analytical HPLC utilized a Beckman Coulter Ultrasphere C 18 
